Evidence map›Paper›PMID 42540609›Full record

ArticleArchives of medical science : AMS2026

Secondary cancers in breast cancer survivors. A two-centre study.

Mateusz Wichtowski, Paulina Gibowska-Maruniak, Paweł Bigos, Łukasz Urbański, Hanna Gryczka, Natalia Bujko-Wasiak, Tomasz Milecki, Kamil Pytlak, Paweł Kurzawa, Katarzyna Brzeźniakiewicz-Janus and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mateusz WichtowskiDepartment of Surgical Oncology, Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Paulina Gibowska-MaruniakDepartment of Surgical Oncology, Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Paweł BigosDepartment of Surgical Oncology, Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Łukasz UrbańskiDepartment of Surgical Oncology, Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Hanna GryczkaDepartment of Pathomorphology, Poznan University of Medical Sciences, Poznan, Poland.
Natalia Bujko-WasiakDepartment and Clinic of Haematology, Oncology, and Radiotherapy of the University of Zielona Gora, Gorzow Wielkopolski, Poland.
Tomasz MileckiDepartment of Urology, Poznan University of Medical Sciences, Poznan, Poland.
Kamil PytlakIndependent Researcher, Wroclaw, Poland.
Paweł KurzawaDepartment of Oncological Pathology, University Clinical Hospital, Poznan University of Medical Sciences, Poznan, Poland.
Katarzyna Brzeźniakiewicz-JanusDepartment and Clinic of Haematology, Oncology, and Radiotherapy of the University of Zielona Gora, Gorzow Wielkopolski, Poland.
Lidia GilDepartment of Haematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The risk of secondary cancers in breast cancer survivors remains a significant concern. This study aimed to evaluate the association between treatment modalities and the time to development of secondary cancers in patients after mastectomy or breast-conserving therapy (BCT). Material and methods: A retrospective analysis was conducted on 6590 patients from 2 centres (Poznan and Gorzow, Poland) treated for breast cancer between 2017 and 2022. A total of 149 patients from this group developed secondary cancer. Data included demographic and clinical characteristics, treatment types (chemotherapy, hormonotherapy, radiotherapy), and subtypes of primary breast cancer (luminal, triple negative, HER2 positive). Statistical methods included Kaplan-Meier analysis, Cox proportional hazards models, and χ Results: The median time to secondary cancer detection was significantly shorter in patients with TNBC/HER2+ subtypes (2.8 years) compared to luminal subtypes (6.1 years; Conclusions: The subtype of primary breast cancer significantly influences the time to secondary cancer development, with TNBC/HER2+ patients at higher risk. Treatment modalities did not significantly affect secondary cancer risk, but combined therapies may offer protective effects. These findings highlight the need for tailored surveillance strategies based on tumour biology.

Indexed as

breast cancerbreast-conserving therapyHER2+mastectomysecondary cancersTNBCtreatment modalities

Identifiers

PMID42540609
PMCPMC13426188

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.